Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
P/E Ratio
--
P/B Ratio
0.78
Industry P/E
--
Debt to Equity
1.12
ROE
-0.69 %
ROCE
-34.59 %
Div. Yield
0 %
Book Value
0.01
EPS
-0.01
CFO
$-206.19 Mln
EBITDA
$-229.81 Mln
Net Profit
$-248.64 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
BioLineRx - ADR
| -66.36 | -8.86 | -40.94 | -88.74 | -63.98 | -47.05 | -45.86 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
BioLineRx - ADR
| -86.15 | 166.10 | -71.08 | -19.05 | 12.00 | -65.70 | -59.68 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.62 | 200.22 | -- | 299.46 | |
| 6.74 | 177.09 | -- | -40.76 | |
| 1.24 | 162.64 | -- | -136.88 | |
| 0.64 | 20.07 | 5.58 | 33.7 |
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the... treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. Address: Modi?in Technology Park, Hevel Modi'in, Israel, 7177871 Read more
Chief Executive Officer
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Chief Executive Officer
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Headquarters
Hevel Modi'in
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of BioLineRx Ltd - ADR stood at $ 39 Mln as on 31-Dec-24
The share price of BioLineRx Ltd - ADR is $2.88 (NASDAQ) as of 17-Apr-2025 16:00 EDT. BioLineRx Ltd - ADR has given a return of -63.98% in the last 3 years.
BioLineRx Ltd - ADR has a market capitalisation of $ 10 Mln as on 17-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of BioLineRx Ltd - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BioLineRx Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of BioLineRx Ltd - ADR.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. Address: Modi?in Technology Park, Hevel Modi'in, Israel, 7177871
The CEO & director of Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA. is BioLineRx Ltd - ADR, and CFO & Sr. VP is Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA.
There is no promoter pledging in BioLineRx Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
18
|
|
|
16
|
|
|
2
|
| BioLineRx Ltd. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-69.11
|
|
Operating margin(%)
|
-0.51
|
|
Net Margin(%)
|
-31.86
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of BioLineRx Ltd - ADR was $0 Mln.
$0.13
(
